Older women with genomically high-risk hormone receptor (HR)-positive breast cancer did not benefit from adjuvant ...

Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

The mechanism we delineated … can be targeted at multiple levels with existing drugs, potentially improving disease outcomes in this patient population,” said Lorenzo Galluzzi, PhD.

These endocrine therapy are effective in treating hormone receptor positive breast cancer by targeting the specific pathway that drives tumor growth. By blocking estrogen and progesterone on ...

Similarly, if the tumor cells contain progesterone receptors, the cancer is called progesterone receptor–positive (PR-positive). Approximately 70% of breast cancers are ER-positive.

Hormone therapy to reduce levels of estrogen in breast cancer patients, which has long been used for the purposes of tumor reduction prior to surgical extraction, may cause some tumors to mutate ...

At 12-year follow-up, C9741 confirmed the sustained long-term benefit of adjuvant dose-dense chemotherapy for node-positive breast cancer. SET2,3 identified patients with ER+ breast cancer who ...

Estrogen Receptor-Positive (ER+) breast cancer is the most common type of breast cancer, accounting for about 70–80% of all cases [1], [4]. This form of cancer is characterized by cells that ...